Literature DB >> 20579914

Prolonged paradoxical response to anti-tuberculous treatment after infliximab.

Sara Melboucy-Belkhir1, Gabriella Flexor, Jérôme Stirnemann, Anne-Sophie Morin, Latifatou Boukari, Claude Polliand, Philippe Cruaud, Olivier Fain.   

Abstract

A 56-year-old woman with ankylosing spondylitis, treated for 3 months with infliximab, developed miliary tuberculosis with mediastinal lymphadenopathies and brain and splenic lesions. After initial improvement under anti-tuberculous therapy, she suffered an unexpectedly prolonged paradoxical worsening with several episodes of lymphadenopathy, including life-threatening ones, over a period of more than 14 months of follow-up. The outcome was favorable as a result of corticosteroid and surgical treatments. This phenomenon reflects a paradoxical reaction precipitated by infliximab withdrawal.
Copyright © 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20579914     DOI: 10.1016/j.ijid.2010.03.002

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  6 in total

1.  [Immune reconstitution syndrome].

Authors:  D Meyer-Olson; D Ernst; M Stoll
Journal:  Z Rheumatol       Date:  2012-04       Impact factor: 1.372

Review 2.  Immune reconstitution inflammatory syndrome associated with biologic therapy.

Authors:  Malika Gupta; Kashif Jafri; Rebecca Sharim; Susanna Silverman; Sayantani B Sindher; Anupama Shahane; Mildred Kwan
Journal:  Curr Allergy Asthma Rep       Date:  2015-02       Impact factor: 4.919

3.  Prolonged paradoxical reaction to anti-tuberculous treatment after discontinuation of TNF-alpha- blocker therapy with adalimumab. Rare clinical documentation.

Authors:  Roger Fei Falkenstern-Ge; Kim Husemann; Martin Kohlhäufl
Journal:  Open Med (Wars)       Date:  2014-10-08

4.  Ground-glass opacity as a paradoxical reaction in miliary tuberculosis: A case report and review of the literature.

Authors:  Yuki Tokuyama; Takeshi Matsumoto; Yusuke Kusakabe; Naoki Yamamoto; Kensaku Aihara; Shinpachi Yamaoka; Michiaki Mishima
Journal:  IDCases       Date:  2019-12-19

5.  Treatment with Tumor Necrosis Factor-α Inhibitors, History of Allergy, and Hypercalcemia Are Risk Factors of Immune Reconstitution Inflammatory Syndrome in HIV-Negative Pulmonary Tuberculosis Patients.

Authors:  Yoshimasa Hachisu; Yasuhiko Koga; Shu Kasama; Kyoichi Kaira; Masakiyo Yatomi; Haruka Aoki-Saito; Hiroaki Tsurumaki; Yosuke Kamide; Noriaki Sunaga; Toshitaka Maeno; Tamotsu Ishizuka; Takeshi Hisada
Journal:  J Clin Med       Date:  2019-12-30       Impact factor: 4.241

Review 6.  Use of steroids to treat anti-tumor necrosis factor α induced tuberculosis-associated immune reconstitution inflammatory syndrome: Case report and literature review.

Authors:  Daijiro Nabeya; Takeshi Kinjo; Kazutaka Yamaniha; Shoshin Yamazato; Reo Tome; Kazuya Miyagi; Hideta Nakamura; Tetsu Kinjo; Shusaku Haranaga; Futoshi Higa; Jiro Fujita
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.